Johnson & Johnson vs Hershey Company (The)
Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Hershey PA chocolate and snacks (NYSE: HSY) ~$10.2B FY2024 revenue; Reese's #1 US candy brand, cocoa inflation $2.5K→$12K/MT crisis, SkinnyPop salty snacks, competing with Mars and Ferrero.
About
The Hershey Company is a Hershey, Pennsylvania-based confectionery and snacks company — publicly traded on the New York Stock Exchange (NYSE: HSY) as an S&P 500 Consumer Staples component — manufacturing and selling chocolate, candy, mints, gum, and salty snacks through iconic brands including Hershey's (chocolate bars, Kisses), Reese's (peanut butter cups — America's #1 candy brand by revenue), Kit Kat (licensed from Nestlé for the US market), York Peppermint Patties, Jolly Rancher, Ice Breakers, Skinny Pop, Dot's Pretzels, and Pirate's Booty through approximately 18,000 employees in 80+ countries. In fiscal year 2024, Hershey reported net sales of approximately $10.2 billion, with earnings per share significantly compressed by unprecedented cocoa commodity inflation: West African cocoa prices (Ghana and Ivory Coast provide 70%+ of global cocoa supply) surged from $2,500/metric ton in 2022 to over $12,000/metric ton in early 2024 — the highest prices in 50+ years — driven by El Niño-related drought and crop disease (swollen shoot disease) reducing cocoa harvests, creating a chocolate manufacturer cost crisis that Hershey absorbed through price increases and hedging while managing volume declines as consumers resisted higher candy prices. CEO Michele Buck has guided Hershey through the cocoa inflation crisis by implementing 10-15% retail price increases in 2023-2024, reformulating some lower-margin products to reduce cocoa content, and hedging cocoa commodity exposure on a rolling 12-18 month forward basis to smooth out extreme spot price volatility.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.